Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Subscribe To Our Newsletter & Stay Updated
